Karo Bio announced it has achieved first milestone in Pfizer collaboration
Thursday, 05 September 2013
The collaboration between Karo Bio AB and Pfizer Inc. has successfully
resulted in a significant achievement within the RORgamma project
triggering the first milestone payment to Karo Bio.
In a press release, Karo Bio AB writes that the purpose of the
collaboration is to develop drugs for treatment of autoimmune diseases.
“The teams from Karo Bio and Pfizer have enjoyed an excellent
interaction and relationship which has helped meet this goal. This
achievement clearly demonstrates the value Karo Bio brings to its
partners in the area of nuclear receptor drug discovery”, says Karo
Bio’s CEO Per Bengtsson.
The collaboration that started in December 2011, aims to discover
and develop novel small molecule RORgamma modulators for the treatment
of autoimmune diseases. The nuclear hormone receptor RORgamma is a
novel attractive target for the treatment of autoimmune diseases like
rheumatoid arthritis, multiple sclerosis and psoriasis. RORgamma
directly controls the production and secretion of the cytokine IL-17, a
major contributor to inflammation. The receptor’s key role in driving
disease pathology has been implicated in clinical trials using
monoclonal antibodies that neutralize IL-17 activity.